Physician profile
Daniela Weatherly
NPI 1184691859
$5,303.87
in general payments reported to CMS, 2019-2025
43 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $1,241 · 2021: $1,645 · 2022: $153 · 2023: $270 · 2024: $398 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $751.32 | 2019-2025 | Wegovy |
| Abbvie INC. | $525.20 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $480.11 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $318.25 | 2019-2021 | |
| Amarin Pharma, INC. | $316.37 | 2019-2023 | |
| Pfizer INC. | $265.37 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $261.58 | 2019-2024 | |
| Allergan, INC. | $247.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $214.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $197.22 | 2019-2024 | Farxiga |
| Sumitomo Pharma America, INC. | $189.83 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.41 | 2019-2021 | |
| Corcept Therapeutics | $107.32 | 2020-2021 | |
| Almatica Pharma LLC | $106.73 | 2023-2025 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.35 | 2019-2024 | Xifaxan, Trulance |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Weatherly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.